发明名称
摘要 The present invention is directed to the use of the peptide compound Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
申请公布号 JP2010539020(A) 申请公布日期 2010.12.16
申请号 JP20100523393 申请日期 2008.09.09
申请人 发明人
分类号 C07K14/52;A61K9/08;A61K9/19;A61K38/00;A61K38/22;A61P1/00;A61P1/02;A61P1/04;A61P1/10;A61P1/16;A61P3/00;A61P3/10;A61P7/02;A61P7/04;A61P7/06;A61P7/10;A61P7/12;A61P9/00;A61P9/02;A61P9/04;A61P9/06;A61P9/08;A61P9/10;A61P9/12;A61P11/00;A61P11/06;A61P13/10;A61P13/12;A61P15/00;A61P15/06;A61P15/08;A61P15/10;A61P17/00;A61P17/02;A61P17/06;A61P17/14;A61P19/02;A61P19/06;A61P19/08;A61P19/10;A61P21/00;A61P21/04;A61P25/00;A61P25/14;A61P25/16;A61P25/18;A61P25/20;A61P25/22;A61P25/24;A61P25/28;A61P25/32;A61P25/34;A61P25/36;A61P27/02;A61P27/06;A61P27/12;A61P27/14;A61P27/16;A61P29/00;A61P31/00;A61P31/04;A61P31/06;A61P31/12;A61P31/14;A61P31/16;A61P31/18;A61P31/20;A61P31/22;A61P33/02;A61P33/04;A61P33/06;A61P33/08;A61P33/10;A61P33/12;A61P33/14;A61P35/00;A61P35/02;A61P35/04;A61P37/02;A61P37/06 主分类号 C07K14/52
代理机构 代理人
主权项
地址
您可能感兴趣的专利